- Home
- CAPR vs SJT Comparison
CAPR vs SJT Comparison
Compare CAPR & SJT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- SJT
- Stock Information
- Founded
- CAPR 2005
- SJT 1980
- Country
- CAPR United States
- SJT United States
- Employees
- CAPR N/A
- SJT N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- SJT Oil & Gas Production
- Sector
- CAPR Health Care
- SJT Energy
- Exchange
- CAPR Nasdaq
- SJT Nasdaq
- Market Cap
- CAPR 324.6M
- SJT 269.4M
- IPO Year
- CAPR N/A
- SJT N/A
- Fundamental
- Price
- CAPR $7.62
- SJT $6.14
- Analyst Decision
- CAPR Strong Buy
- SJT
- Analyst Count
- CAPR 7
- SJT 0
- Target Price
- CAPR $24.71
- SJT N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- SJT 194.8K
- Earning Date
- CAPR 11-12-2025
- SJT 11-13-2025
- Dividend Yield
- CAPR N/A
- SJT N/A
- EPS Growth
- CAPR N/A
- SJT N/A
- EPS
- CAPR N/A
- SJT N/A
- Revenue
- CAPR $13,392,150.00
- SJT $42,635.00
- Revenue This Year
- CAPR N/A
- SJT N/A
- Revenue Next Year
- CAPR $7,894.07
- SJT N/A
- P/E Ratio
- CAPR N/A
- SJT N/A
- Revenue Growth
- CAPR N/A
- SJT N/A
- 52 Week Low
- CAPR $5.68
- SJT $3.66
- 52 Week High
- CAPR $23.40
- SJT $7.22
- Technical
- Relative Strength Index (RSI)
- CAPR 54.02
- SJT 58.21
- Support Level
- CAPR $7.11
- SJT $5.76
- Resistance Level
- CAPR $8.06
- SJT $6.61
- Average True Range (ATR)
- CAPR 0.51
- SJT 0.23
- MACD
- CAPR 0.16
- SJT 0.04
- Stochastic Oscillator
- CAPR 72.64
- SJT 58.06
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.